Abstract:
:Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. 19-28z CAR T cells express a fusion protein comprised of an anti-CD19 mAb fused with CD28 costimulatory and CD3-zeta-chain signaling domains. The current paper demonstrates that administration of 19-28z CAR T cells in patients with relapsed or refractory B-ALL in a Phase I clinical trial has led to 88% of patients undergoing complete remission. Despite the benefits, CAR T-cell therapy is associated with cytokine release syndrome toxicities. The authors demonstrated criteria to diagnose severe cytokine release syndrome (sCRS) and treated sCRS with either high-dose steroids or with tocilizumab, an IL-6 receptor-specific mAb. Although both alleviated sCRS, steroid treatment negated the beneficial effects of CAR T-cell therapy, whereas tocilizumab did not. Taken together, CAR T-cell immunotherapy can be used as a safe and effective approach against tumors with known tumor-associated antigens.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Patel JM,Dale GA,Vartabedian VF,Dey P,Selvaraj Pdoi
10.2217/imt.14.44subject
Has Abstractpub_date
2014-01-01 00:00:00pages
675-8issue
6eissn
1750-743Xissn
1750-7448journal_volume
6pub_type
评论,杂志文章相关文献
Immunotherapy文献大全abstract::Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.7
更新日期:2015-01-01 00:00:00
abstract:AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2016-0068
更新日期:2016-10-01 00:00:00
abstract::Osteoarthritis is a disabling disease of the aging generation, which results in loss of quality of life and increased healthcare costs. Cytokines appear to play an important role in the cartilaginous degeneration characterizing the pathological process. Increasing experience is being gained with cytokine-modulating th...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.14
更新日期:2009-05-01 00:00:00
abstract::TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.111
更新日期:2013-10-01 00:00:00
abstract::Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.11.135
更新日期:2011-12-01 00:00:00
abstract::The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cel...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/1750743X.1.1.27
更新日期:2009-01-01 00:00:00
abstract::After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0029
更新日期:2017-06-01 00:00:00
abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...
journal_title:Immunotherapy
pub_type: 面试,新闻
doi:10.2217/imt.13.27
更新日期:2013-05-01 00:00:00
abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.5
更新日期:2011-03-01 00:00:00
abstract:AIM:To assess carnitine serum levels and possible risk factors of its deficiency in patients with TB. PATIENTS & METHODS:All newly diagnosed TB patients admitted to an infectious diseases ward were recruited. Demographic, clinical and paraclinical characteristics of the patients were collected. Total carnitine serum c...
journal_title:Immunotherapy
pub_type: 临床试验,杂志文章
doi:10.2217/imt.13.90
更新日期:2013-09-01 00:00:00
abstract::Evaluation of: Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patents. Sci. Transl. Med. 4(134), 134ra62 (2012). Tregs are involved in the maintenance of immunological self-tolerance. Recent studies have revealed that Tregs ...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.12.116
更新日期:2012-11-01 00:00:00
abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0019
更新日期:2017-05-01 00:00:00
abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.68
更新日期:2013-08-01 00:00:00
abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.43
更新日期:2010-09-01 00:00:00
abstract::Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.1
更新日期:2015-01-01 00:00:00
abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.47
更新日期:2013-07-01 00:00:00
abstract::Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most dramatic primary brain cancer with a very poor prognosis due to inevitable disease recurrence. Less than 10% of GBM patients are still alive 5 years after diagnosis despite a multimodal treatment with surgical resection of the tumor, radiation therap...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.39
更新日期:2011-04-01 00:00:00
abstract::Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.43
更新日期:2015-01-01 00:00:00
abstract::Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.57
更新日期:2015-01-01 00:00:00
abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0052
更新日期:2016-10-01 00:00:00
abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.36
更新日期:2009-07-01 00:00:00
abstract::Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0006
更新日期:2020-08-01 00:00:00
abstract::Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.29
更新日期:2015-01-01 00:00:00
abstract::FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...
journal_title:Immunotherapy
pub_type:
doi:10.2217/imt-2017-0079
更新日期:2017-09-01 00:00:00
abstract::There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, n...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0051
更新日期:2017-09-01 00:00:00
abstract::Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.66
更新日期:2015-01-01 00:00:00
abstract::Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0217
更新日期:2021-03-01 00:00:00
abstract::Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0266
更新日期:2021-02-01 00:00:00
abstract::Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date,...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.101
更新日期:2016-01-01 00:00:00
abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0202
更新日期:2020-12-01 00:00:00